Literature DB >> 15940648

Infliximab for ulcerative colitis: finally some answers.

Geert D'Haens.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15940648     DOI: 10.1053/j.gastro.2005.04.019

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  6 in total

Review 1.  Advances in biologic therapy for ulcerative colitis and Crohn's disease.

Authors:  Geert D'Haens; Marco Daperno
Journal:  Curr Gastroenterol Rep       Date:  2006-12

Review 2.  The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease.

Authors:  Makoto Naganuma; Toshimitsu Fujii; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2010-12-04       Impact factor: 7.527

Review 3.  Review and clinical perspectives for the use of infliximab in ulcerative colitis.

Authors:  R Panaccione; R N Fedorak; G Aumais; Edmond-Jean Bernard; C N Bernstein; A Bitton; K Croitoru; L A Dieleman; R Enns; B G Feagan; D Franchimont; G R Greenberg; Anne-Marie Griffiths; J K Marshall; P Pare; S Patel; R Penner; C Render; E Seidman; A Hillary Steinhart
Journal:  Can J Gastroenterol       Date:  2008-03       Impact factor: 3.522

Review 4.  Clinical pharmacokinetics and use of infliximab.

Authors:  Ulrich Klotz; Alexander Teml; Matthias Schwab
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.

Authors:  Garrett Lawlor; Alan C Moss
Journal:  Clin Exp Gastroenterol       Date:  2009-12-10

Review 6.  Efficacy and safety of tumor necrosis factor-α blockers for ulcerative colitis: A systematic review and meta-analysis of published randomized controlled trials.

Authors:  Yun-Na Song; Ping Zheng
Journal:  J Food Drug Anal       Date:  2014-11-15       Impact factor: 6.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.